Free Trial
OTCMKTS:BAYRY

Bayer Aktiengesellschaft 8/6/2025 Earnings Report

Bayer Aktiengesellschaft logo
$7.53 +0.13 (+1.76%)
As of 08/8/2025 04:00 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.35
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.42 billion
Expected Revenue
$10.79 billion
Beat/Miss
Beat by +$1.63 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Altucher: $900 to $108,000? Trump’s “Great Gain” Is Here
James Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump policy move, and the other tied to a proven financial pattern that previously minted over 80,000 new millionaires. He believes a small $900 investment could turn into a $108,000 windfall within 12 months—and this may be the last chance for everyday investors to catch it.
Bayer’s Aficamten Study: A New Hope for oHCM Treatment
Goldman Sachs Sticks to Their Buy Rating for Bayer (0P6S)
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY), together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

View Bayer Aktiengesellschaft Profile

More Earnings Resources from MarketBeat